Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6.61
9.74
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Zhejiang Hisun Pharmaceutical Co Ltd
Long-Term Debt
Zhejiang Hisun Pharmaceutical Co Ltd
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Z
|
Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267
|
Long-Term Debt
¥1.4B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-6%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Long-Term Debt
¥104.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Long-Term Debt
¥158.1m
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-6%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Long-Term Debt
¥58.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
19%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Long-Term Debt
¥195.6m
|
CAGR 3-Years
43%
|
CAGR 5-Years
118%
|
CAGR 10-Years
42%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Long-Term Debt
¥192.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Zhejiang Hisun Pharmaceutical Co Ltd
Glance View
Zhejiang Hisun Pharmaceutical Co., Ltd. unfolds its story in the competitive arena of China's booming pharmaceutical industry. Founded in 1956, Hisun has gradually matured from a regional player into a recognized name in global generic and specialty drug manufacturing. The company's core strength lies in its integration across the pharmaceutical supply chain, which allows it to produce active pharmaceutical ingredients (APIs) while also scaling up to final dosage forms. Hisun capitalizes on its robust research and development capabilities, investing heavily in innovation to expand its diverse pharmaceutical product portfolio. Through strategic partnerships and collaborative ventures, such as alliances with leading biotech firms, Hisun not only enhances its technological footprint but fortifies its international presence, poised to address the increasing global demand for affordable healthcare solutions. In the sprawling marketplace, Hisun’s financial model is driven by its synergistic blend of producing generic medications and investing in biopharmaceuticals. The firm enjoys a lucrative revenue stream by tapping into the cost-effective production of APIs, which are integral to numerous medications worldwide. Through vertically integrated operations, the company achieves economies of scale, facilitating competitive pricing. Hisun’s foray into more value-added, complex generics and biosimilars further diversifies its income channels, transforming challenges into opportunities amid stringent global regulatory landscapes. By navigating these complexities, Hisun strengthens its market position, leveraging a balance between solid internal growth and strategic global outreach, thus sustaining its journey within the dynamic panorama of the pharmaceutical sector.
See Also
What is Zhejiang Hisun Pharmaceutical Co Ltd's Long-Term Debt?
Long-Term Debt
1.4B
CNY
Based on the financial report for Sep 30, 2024, Zhejiang Hisun Pharmaceutical Co Ltd's Long-Term Debt amounts to 1.4B CNY.
What is Zhejiang Hisun Pharmaceutical Co Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
-6%
Over the last year, the Long-Term Debt growth was -46%. The average annual Long-Term Debt growth rates for Zhejiang Hisun Pharmaceutical Co Ltd have been -24% over the past three years , -18% over the past five years , and -6% over the past ten years .
You don't have any saved screeners yet
